Slashed Activities, Reduced Sales: Commercial Crackdown Dents Drug Makers In China
Plus VBP, unfavorable exchange rates
Among multinationals, AstraZeneca has reported its commercial activities have been negatively impacted by China's broad anti-corruption campaign, while J&J has seen some affect from the country's volume-based procurement scheme. Roche, Lilly and Novartis have also reported some softness in the last quarter versus the previous three months.
